Integral Health Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Integral Health Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,000	Closed	-$3.22M	–	104
2023 Q1	$3.22M	Buy	30,000 +10,000	+50%	+$1.15M	0.65%	54
2022 Q4	$2.2M	Buy	+20,000	New	+$1.3M	0.46%	55

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Integral Health Asset Management's RXDX Position: Q2 2023 in Review

Integral Health Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 30,000 shares — an estimated $3.22M sold.

Integral Health Asset Management first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $3.22M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Integral Health Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Integral Health Asset Management sold 30,000 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $3.22M.
Integral Health Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Integral Health Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $3.22M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Integral Health Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.